Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorArtac, Mehmet
dc.contributor.authorYildirim, Selman
dc.contributor.authorInal, Ali
dc.contributor.authorDede, Isa
dc.contributor.authorGuler, Tunc
dc.contributor.authorBoruban, Melih Cem
dc.date.accessioned2024-02-23T14:00:02Z
dc.date.available2024-02-23T14:00:02Z
dc.date.issued2015
dc.departmentNEÜen_US
dc.description.abstractIdentification of biomarkers used for the prognostic evaluation of non-small cell lung cancer (NSCLC) patients is important. The aim of this study was to evaluate the potential prognostic value of XRCC1, ERCC1, ERCC2, and TP53 single nucleotide polymorphisms (SNPs) in completely resected NSCLC patients. In total, 130 patients, surgically treated for NSCLC between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. XRCC1 Arg399Gln, ERCC1 Asn118Asn, ERCC2 Lys751Gln, and TP53 Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78 years. Median relapse-free survival duration (RFS) was found as 46.2 months. In those with ERCC2 CC allele, median RFS was detected as 28.3 months (95 % confidence interval (CI), 20.8-35.8), 46.9 months in those with CT heterozygous (95 % CI, 18.6-75.2), and 80.1 months for those with TT mutant allel (95 % CI, 33.0-127.2). Median RFS was seen to be longer in mutant group and also statistically significant (P = 0.018). Additionally, upon evaluating CC normal group with CT + TT alleles including mutant alleles, median RFS was found as 56.5 months (95 % CI, 24.6-88.4) in CT + TT group, and this was statistically significant (P = 0.005) Also, median RFS was 15.1 months in those including ERCC2 CC allele and 56.5 months in CT + TT allele in the group with no adjuvant treatment (P = 0.001). In conclusion, our study showed that ERCC2/XPD polymorphism is an independent prognostic factor in operated NSCLC patients, and these findings should be supported with prospective studies.en_US
dc.description.sponsorshipSelcuk University in Konya, Turkey [11102028]en_US
dc.description.sponsorshipThe study was approved by the Ethical Board of the Meram Medical School of Selcuk University and performed with the financial support of the Scientific Research Project of Selcuk University (Project no: 11102028) in Konya, Turkey.en_US
dc.identifier.doi10.1007/s13277-015-3066-2
dc.identifier.endpage4285en_US
dc.identifier.issn1010-4283
dc.identifier.issn1423-0380
dc.identifier.issue6en_US
dc.identifier.pmid25596702en_US
dc.identifier.scopus2-s2.0-84938985339en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage4279en_US
dc.identifier.urihttps://doi.org/10.1007/s13277-015-3066-2
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11429
dc.identifier.volume36en_US
dc.identifier.wosWOS:000359383700032en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumor Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectGene Polymorphismsen_US
dc.subjectXrcc1en_US
dc.subjectErcc1en_US
dc.subjectXpden_US
dc.subjectP53en_US
dc.titlePrognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu